Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

Streck launches new blood collection tube

Products are for professional/laboratory use only.

Abacus dx is pleased to announce the newest addition to Streck’s trusted blood collection tube portfolio, RNA Complete BCT™.

The new blood collection tube maintains draw time cell-free RNA concentration while limiting the release of extracellular vesicles, such as exosomes, from blood cells. RNA Complete BCT™ maintains these important analytical targets for up to seven days when stored at room temperature, allowing convenient sample collection, transport, and storage.

Features of RNA Complete BCT™:

  • Seven day sample stability when stored at room temperature
  • Isolated cfRNA is suitable for downstream applications, including ddPCR and NGS
  • Compatible with commercially available total plasma nucleic acid isolation kits
  • Isolated extracellular vesicles are suitable for downstream applications including NTA or indirect analysis or EV-associated cargo
  • Compatible with standard low input RNA library prep kits

For Research Use Only

 


Discover Streck RNA Complete BCT™

Download Flyer >

Want to know more about Streck RNA Complete BCT™?

Contact Us Now >



Request a Quote

Request Quote

Recent Posts

2027 Abacus dx Emerging Investigators Grant

COMING SOON Grant in Research Funding Empowering the Next Generation of Scientific Leaders Stay tuned for the 2027 Abacus dx Emerging Investigators Grant. More information…

Read full article

Mindray – CAL 9000

CAL 9000 – All-in-One Solution: Total Automation for Optimal Workflow Mindray CAL‑9000, an all‑in‑one cellular analysis line designed to maximise efficiency and consistency across the…

Read full article

Developing Diagnostic Kits for Ovarian Cancer

In Australia, ovarian cancer is the deadliest reproductive cancer. The average five‑year survival rate sits at around 49%, compared with about 92% for breast cancer,…

Read full article